ASB Consultores’s West Pharmaceutical WST Stock Holding History

ASB Consultores’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-505	Closed	-$237K	–	249
2021 Q4	$237K	Buy	+505	New	+$217K	0.12%	196

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

ASB Consultores's WST Position: Q1 2022 in Review

ASB Consultores sold out of West Pharmaceutical (WST) in Q1 2022, closing a stake of 505 shares — an estimated $237K sold.

ASB Consultores first reported a position in WST in Q4 2021 and held it in 1 quarter. The position peaked at $237K in Q4 2021. 717 funds tracked by Wall St. Rank hold WST as of Q1 2022.

ASB Consultores reported no remaining West Pharmaceutical position as of Q1 2022 after selling out during the quarter.
ASB Consultores sold 505 West Pharmaceutical shares in Q1 2022, an estimated $237K.
ASB Consultores first reported a position in West Pharmaceutical in Q4 2021 and held it in 1 quarter.
ASB Consultores's West Pharmaceutical position peaked at $237K in Q4 2021.
717 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2022.

Based on ASB Consultores's 13F filing for Q1 2022, filed 11 Jan 2023.